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Vitamin C Inhibits Endothelial Cell Apoptosis in
Congestive Heart Failure
Lothar Rössig, MD; Jörg Hoffmann, BSc; Bénédicte Hugel, PhD; Ziad Mallat, MD, PhD;
Astrid Haase; Jean-Marie Freyssinet, PhD; Alain Tedgui, PhD; Alexandra Aicher, MD;
Andreas M. Zeiher, MD; Stefanie Dimmeler, PhD
Background—Proinflammatory cytokines like tumor necrosis factor-a and oxidative stress induce apoptotic cell death in
endothelial cells (ECs). Systemic inflammation and increased oxidative stress in congestive heart failure (CHF) coincide
with enhanced EC apoptosis and the development of endothelial dysfunction. Therefore, we investigated the effects of
antioxidative vitamin C therapy on EC apoptosis in CHF patients.
Methods and Results—Vitamin C dose dependently suppressed the induction of EC apoptosis by tumor necrosis factor-a
and angiotensin II in vitro as assessed by DNA fragmentation, DAPI nuclear staining, and MTT viability assay. The
antiapoptotic effect of vitamin C was associated with reduced cytochrome C release from mitochondria and the
inhibition of caspase-9 activity. To assess EC protection by vitamin C in CHF patients, we prospectively randomized
CHF patients in a double-blind trial to vitamin C treatment versus placebo. Vitamin C administration to CHF patients
markedly reduced plasma levels of circulating apoptotic microparticles to 3268% of baseline levels, whereas placebo
had no effect (87614%, P,0.005). In addition, vitamin C administration suppressed the proapoptotic activity on EC
of the serum of CHF patients (P,0.001).
Conclusions—Administration of vitamin C to CHF patients suppresses EC apoptosis in vivo, which might contribute to
the established functional benefit of vitamin C supplementation on endothelial function. (Circulation. 2001;104:2182-
2187.)
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Exercise intolerance in congestive heart failure (CHF)results from vasotone dysregulation caused by impaired
endothelial function.1–3 The formation of reactive oxygen
species (ROS) is enhanced during the progression of CHF4,5
and was hypothesized to contribute to endothelial dysfunc-
tion.6 In accordance with this model, antioxidative treatment
improves endothelial function in CHF patients.7
We and others have previously shown that serum of CHF
patients induces apoptosis in cultured endothelial cells
(ECs).8,9 Importantly, the levels of apoptotic membrane
microparticles are elevated in the circulation of CHF pa-
tients.9 Increasing evidence suggests that oxidative stress
regulates apoptosis of ECs. Thus, prooxidant stimuli like
H2O2 induce EC apoptosis.10,11 Moreover, cytokine messen-
gers, tumor necrosis factor-a (TNF-a), and the vasoconstric-
tor peptide angiotensin II (Ang II) trigger apoptosis of EC and
stimulate the generation of ROS.12 Thus, enhanced oxidative
stress may contribute to endothelial dysfunction in heart
failure by the induction of EC apoptosis.13,14
Therefore, this study was designed to investigate the
influence of the antioxidant vitamin C15 on TNF-a–, Ang II–,
and CHF serum–induced apoptosis signaling in ECs in vitro.
In addition, we performed a prospectively randomized,
placebo-controlled, double-blind clinical trial to investigate
the functional effects of vitamin C therapy on EC apoptosis in
patients with CHF.
Methods
Patients
We studied 34 patients (26 men, 8 women; age, 28 to 76 years) who
suffered from CHF symptoms according to NYHA classes II through
IV. The clinical characteristics of these patients are shown in the
Table. All patients received standard treatment for heart failure,
including ACE inhibitors/angiotensin receptor-1 blockers, diuretics,
b-blockers, and for many digitalis. Patients with elevated serum
creatinine levels ($2.0 mg/dL) and those with concomitant infec-
tious or primary pulmonary disease were excluded. None of the
patients had a history of myocardial infarction within 3 months of the
onset of treatment. Written, informed consent was obtained from all
patients included in this study. The study protocol was approved by
the Research Ethics Committee of the Johann Wolfgang Goethe
University of Frankfurt.
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Study Protocol
Patients were randomized to receive vitamin C or placebo according
to a sequential administration protocol combining initial intravenous
bolus with prolonged oral application of the treatment and placebo
substances. Initially, a baseline serum sample was drawn, followed
by a 10-minute bolus infusion of 2.5 g vitamin C (Wörwag Pharma)
or sodium chloride 0.9%. Fifteen minutes later, a second serum
sample was taken. Throughout the next 3 days, patients received 2 g
oral vitamin C or placebo tablets (Merck) twice daily, and a third
serum sample was obtained in the morning of the fifth day.
At each of the 3 respective time points, venous blood samples
were drawn into 10-mL serum tubes without additives, immediately
stored on ice for 30 minutes to allow clotting, and centrifuged at
3500 rpm and 4°C for 10 minutes; then, serum was frozen in aliquots
of 500 mL at 280°C. For use in cell culture, aliquots were thawed on
ice shortly before experiments were performed. To perform shed
membrane particle analysis, blood was drawn into plasma
monovettes containing 0.138 mol/L trisodium citrate at a final
volume ratio (blood:anticoagulant) of 9:1, and sample preparation
was performed according to the method of Aupeix et al.16
Cell Culture
Human umbilical venous ECs (HUVECs) were purchased from Cell
Systems/Clonetics and were cultured in endothelial basal medium
supplemented with hydrocortisone (1 mg/mL), bovine brain extract
(3 mg/mL), gentamicin (50 mg/mL), amphotericin B (50 mg/mL),
epidermal growth factor (10 mg/mL), and 10% FCS until the third
passage. After detachment with trypsin, cells were grown in culture
dishes or flasks for $12 hours before experiments were performed.
Detection of Cell Death In Vitro and In Vivo
For morphological assessment of apoptotic nuclei, 105 cells were
plated in 35-mm culture dishes. Twelve hours before the experiments
were begun, complete medium was changed to endothelial basal
medium with no FCS and no supplements. Then, 10% human serum
or the indicated concentrations of TNF-a or Ang II (both from
Sigma) were added. Eighteen hours later, cells underwent nuclear
staining and were fluoromicroscopically analyzed as described
previously.9 To assess internucleosomal DNA laddering, cells were
plated in culture flasks (106 cells) and underwent the same experi-
mental protocol as described above. Isolation and radioactive label-
ing of DNA and subsequent Southern blot analysis were performed
as described in detail elsewhere.17 Cell viability was determined with
the MTT assay as previously published.17 The amount of apoptotic
microparticles in human plasma samples was measured according to
the method of Aupeix et al16 with a solid-phase prothrombinase
assay. Results were expressed as nanomolar phosphatidylserine
equivalent normalized to a reference curve.
Caspase-9 Activity, Cytochrome C, Thiobarbituric
Acid Reactive Substances, and Cytokine Assays
For caspase activity measurements, HUVEC were lysed as stated
before.17 Then, proteolytic cleavage of a fluorogenic caspase-9
substrate (Calbiochem, Bad Soden/Taunus) in cell lysates was
measured at excitation and emission wavelengths of 400 and 505 nm,
respectively. Cytochrome C detection in cytoplasmic and nuclear
fractions was performed according to the method of Walter et al.18
TNF-a, soluble TNF-a receptor I (sTNFRI), soluble Fas (sFas), and
soluble Fas Ligand (sFasLigand) serum concentrations were mea-
sured with ELISA kits according to the manufacturer’s instructions
(TNF-a, sTNFRI: R&D Systems; sFas, sFasLigand: Coulter Immu-
notech), and determination of thiobarbituric acid reactive substances
(TBARS) was performed with the OXI-TEK TBARS assay kit
(ZeptoMetrix).
Statistical Analysis
Data are expressed as mean6SEM and mean6SD as indicated from
$3 independent experiments. Continuous variables were tested for
normal distribution with the Kolmogorov-Smirnov test. Statistical
analysis was performed by t test for comparison of the 2 treatment
groups (variance analysis by the Levene test) and for multiple groups
by 1-way ANOVA analysis, followed by post-hoc analysis adjusted
with a least-significant-difference correction. Categorical variables
were compared by means of Fisher’s exact test. Statistical signifi-
cance was assumed if a null hypothesis could be rejected at P50.05.
Results
Effect of Vitamin C on TNF-a– and Ang II–Induced
EC Apoptosis
Morphological analysis of cell nuclei demonstrated that
TNF-a elicited an ’3-fold increase in the number of apo-
ptotic ECs (Figure 1A). Coincubation with vitamin C dose
dependently inhibited TNF-a–induced EC apoptosis
(P,0.001; Figure 1A). Suppression of TNF-a–induced apo-
ptosis by vitamin C was confirmed by analysis of DNA
laddering (Figure 1B). TNF-a induced a marked reduction in
cell viability as assessed by MTT assay that was prevented in
the presence of vitamin C (P,0.05). Likewise, vitamin C
completely inhibited apoptosis induction in ECs by Ang II
(P,0.05; Figure 1C). The antiapoptotic effect of vitamin C
depended on endogenous nitric oxide (NO) generation be-
cause coincubation of the NO synthase inhibitor NG-mono-
methyl-L-arginine monoacetate (L-NMMA, 1 mmol/L) with
vitamin C reversed the inhibition of TNF-a–induced apopto-
sis by vitamin C (Figure 1D), whereas L-NMMA had no
effect on the extent of TNF-a–induced apoptosis in the
absence of vitamin C (data not shown).
Apoptosis signaling in ECs involves the release of cyto-
chrome C from mitochondria18 and the subsequent activation
of caspase-9, which initiates execution of the cell death
program.19 Therefore, we investigated whether the antiapo-
ptotic activity of vitamin C interferes with TNF-a–induced
cytochrome C release and caspase-9 activation. Coincubation
of ECs with vitamin C inhibited the translocation of cyto-
chrome C from mitochondria to the cytosol in response to
TNF-a (Figure 1E) and suppressed caspase-9 activation in
response to TNF-a almost to baseline (Figure 1F). Taken
together, these data indicate that vitamin C interferes with
apoptosis signaling in activated ECs via the inhibition of
cytochrome C release from mitochondria and the subsequent
suppression of caspase-9 activation.
Patient Characteristics
Vitamin C (n517) Placebo (n517) P
Age, y 5562 6163 0.08
Sex, M/F 15/2 11/6 NS
NYHA class, II/III/IV 7/7/3 6/9/2 NS
Origin, IHD/NIHD 8/9 10/7 NS
LVEF, % 2763 2462 0.37
Therapy, n (%)
ACE I/AT1 blockers 17 (100) 17 (100) NS
b-Blockers 8 (47) 11 (65) NS
Diuretics 14 (82) 16 (94) NS
Digitalis 13 (76) 13 (76) NS
IHD indicates ischemic heart disease; NIHD, nonischemic heart disease;
LVEF, left ventricular ejection fraction; ACE I, ACE inhibitors; and AT1,
angiotensin receptor-1. Values are mean6SEM or the number of patients in
each category.
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Effects of Vitamin C Therapy on EC Apoptosis in
Patients With CHF
Our next aim was to demonstrate the antiapoptotic effect of
vitamin C therapy in CHF patients in vivo. Therefore, 34
patients were prospectively randomized in a double-blind
fashion to receive either vitamin C or placebo. As the Table
illustrates, there were no significant differences between the
vitamin C and the placebo groups with respect to age, sex,
clinical severity of CHF according to the NYHA classifica-
tion, CHF origin, left ventricular function, and concomitant
therapy.
Vitamin C therapy in CHF patients by combined intrave-
nous and oral treatment significantly reduced apoptosis in-
duction by patient serum to 7666% of baseline (P,0.001
versus baseline), whereas placebo administration had no such
effect (9563%; P,0.02 versus vitamin C; Figure 2A). After
the initial intravenous dose only, vitamin C administration
significantly though to a lesser extent decreased the proapo-
ptotic activity of CHF serum (8267%; P,0.01 versus
baseline, P,0.05 versus placebo). Responses to vitamin C
did not differ between patients with CHF caused by ischemic
heart disease (7469%) and those with nonischemic heart
disease (7867%; P5NS). Ex vivo addition of vitamin C to
the serum of CHF patients also profoundly reduced serum-
induced EC apoptosis induction as assessed by morphological
analysis of DAPI-stained nuclei (Figure 2B) or DNA ladder-
ing (Figure 2C).
To assess the in vivo relevance of our findings and to
exclude that vitamin C remaining in the serum used to
stimulate EC apoptosis contributes to the observed effects on
ex vivo apoptosis induction by CHF patient serum, we
examined whether vitamin C therapy reduced the plasma load
Figure 1. Effect of vitamin C on apoptosis signaling in activated
ECs. A, Dose-dependent inhibition of TNF-a (50 ng/mL)–induced
apoptosis by coincubation with vitamin C determined by nuclear
morphology. Diagrams represent median, total range of values,
and 75% percentile. *P,0.001, n56. B, TNF-a (50 ng/mL)–
induced DNA fragmentation in absence and presence of vitamin
C. C, Effect of coincubation with vitamin C (100 mmol/L) on Ang
II (1 mmol/L)–induced apoptosis determined by nuclear morphol-
ogy. Values are mean6SD. *P,0.05 vs Ang II, n53. D, Effect of
vitamin C (100 mmol/L) on TNF-a–induced apoptosis in absence
or presence of L-NMMA (1 mmol/L). Values are mean6SEM.
*P,0.05, n510. E, Effect of vitamin C (100 mmol/L) on TNF-a
(50 ng/mL)–induced cytochrome C translocation from mitochon-
dria to cytoplasm (top). Actin reprobes of same membrane were
done to confirm equal loading of gel (bottom). Results consis-
tent with representative Western blots shown here were found in
3 individual experiments. E, Effect of vitamin C (100 mmol/L) on
TNF-a (50 ng/mL)–induced caspase-9 activation. *P,0.05, n54.
Figure 2. Effect of vitamin C in vivo and in vitro on apoptosis
induction by serum of patients with CHF. A, Effect of vitamin C
therapy on proapoptotic activity of patient serum (n517 per
group). Data points represent apoptosis rates in HUVEC incu-
bated with patient serum for 18 hours quantified by nuclear
morphology analysis. Lines connect data points from same
patient at baseline and after sequential intravenous and oral
vitamin C treatment (left) or placebo administration (right).
*P,0.05 vs placebo; **P,0.02 vs placebo. B, Effect of ex vivo
coincubation with vitamin C (100 mmol/L) on apoptosis induc-
tion by CHF serum (10%) in HUVEC determined by nuclear
morphology. Box plots give median, total range of values, and
75% percentile. *P,0.001, n59. C, DNA fragmentation in
HUVEC after apoptosis induction by CHF serum (10%) in
absence or presence of vitamin C (100 mmol/L). Top, Ethidium
bromide staining to confirm equal loading of the gel.
2184 Circulation October 30, 2001
 by on June 24, 2010 circ.ahajournals.orgDownloaded from 
of apoptotic membrane microparticles in patients with CHF.
As a measure of the amount of circulating apoptotic residual
bodies, phosphatidylserine-positive shed membrane micro-
particles were quantified in the plasma samples of a subset of
patients. Vitamin C therapy dramatically reduced plasma
levels of apoptotic membrane microparticles from 5.1461.43
to 1.8260.84 nmol/L phosphatidylserine equivalent
(P,0.05), whereas placebo had no significant effect
(4.4661.13 nmol/L before versus 3.5960.85 nmol/L after
administration; P5NS). Figure 3A illustrates the relative
changes in microparticle load normalized to baseline values
of the individual patients receiving vitamin C or placebo.
Vitamin C administration reduced plasma levels of circulat-
ing apoptotic microparticles to 3268% of baseline levels,
whereas placebo had no effect (87614%, P,0.005). Deter-
mination of the EC marker protein CD31 in a subset of
patients confirmed that a significant proportion of the de-
tected residual bodies was of endothelial origin. On vitamin C
treatment, CD31-positive microparticles decreased to about
the same degree as the total amount of microparticles de-
tected by the prothrombinase assay, whereas they remained
unchanged in the placebo group (data not shown). These data
indicate that the observed decrease in total apoptotic micro-
particles can be attributed at least in part to an effect on EC
apoptosis. The reduction of apoptotic microparticles was
significant only after sequential intravenous and oral treat-
ment with vitamin C, whereas the initial single intravenous
bolus dose had no effect different from placebo (Figure 3A).
Taken together, these data suggest that vitamin C therapy
reduces apoptosis in vivo in patients with CHF.
Effect of Vitamin C on Markers of Oxidative
Stress and TNF-a Serum Concentrations in CHF
To examine whether the observed protective effects of
vitamin C administration were associated with an antioxida-
tive effect of vitamin C, we measured plasma TBARS as a
marker of oxidative stress. In accordance with previous
reports,5,20,21 CHF patients revealed significantly higher lev-
els of oxidative stress than healthy control subjects (data not
shown). Vitamin C treatment significantly reduced TBARS,
whereas placebo had no effect (Figure 3B). In addition,
TNF-a serum concentrations in CHF patients were deter-
mined before and after vitamin C administration. As reported
previously, TNF-a levels in CHF patients were significantly
elevated by ’2.5-fold compared with an age- and sex-
matched control population (data not shown). However,
neither vitamin C nor placebo treatment significantly altered
TNF-a serum concentrations (Figure 3C). Likewise, serum
levels of other cytotoxic factors capable to induce EC
apoptosis in vitro, like sFas, sFasLigand, and sTNFRI, were
elevated in CHF patients compared with healthy volunteers
but did not change in response to vitamin C or placebo
administration (data not shown). Therefore, altered serum
levels circulating cytokines do not appear to contribute to the
observed protective effect of vitamin C on EC apoptosis in
CHF patients.
Discussion
Our results demonstrate that vitamin C interferes with apo-
ptosis signaling in ECs stimulated by TNF-a, Ang II activa-
tion, and serum of patients with CHF. The antiapoptotic
activity of vitamin C is associated with the prevention of
mitochondrial cytochrome C release and suppression of
subsequent caspase activation in activated ECs. Vitamin C
treatment in CHF patients is effective in reducing both the
proapoptotic activity of CHF serum and the amount of
circulating apoptotic membrane microparticles. Thus, protec-
tion of ECs from proapoptotic stimuli may contribute to the
observed beneficial effect of vitamin C administration on
endothelial function in CHF patients.
Ellis et al22 have recently shown that the antioxidant
vitamin C both improved endothelial function and reduced
oxidative stress in CHF patients. However, because they
found no correlation between the improvement in endothelial
function and the reduction in systemic oxidative stress, the
Figure 3. Effect of vitamin C therapy on plasma apoptotic mem-
brane microparticles, plasma TBARS, and TNF-a serum levels in
CHF patients. A, Levels of circulating apoptotic membrane
microparticles in plasma samples of CHF patients after vitamin
C therapy (n57) or placebo administration (n511) were quanti-
fied by measurements of phosphatidylserine redistribution and
normalized to baseline numbers in same patient before random-
ization. See text for the detailed study protocol. Values are
mean6SEM. *P,0.005 vs placebo. B, Relative changes in
plasma TBARS as indicator of oxidative stress in CHF patients
treated with vitamin C (n511) or placebo (n57). C, TNF-a serum
levels in CHF patients treated with vitamin C (n514) or placebo
(n513). Values are mean6SEM; differences were not significant.
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authors speculated that additional effects of vitamin C could
account for the observed functional benefit.22 Recent data
established a role for EC apoptosis in the pathophysiological
sequelae of CHF by demonstrating elevated plasma concen-
trations of apoptotic membrane microparticles in CHF pa-
tients.9 Moreover, increased EC apoptosis was shown to
correlate with a depressed endothelial vasodilator response to
acetylcholine.14 Thus, suppression of EC apoptosis provides a
potential site of interaction by which vitamin C could
interfere with the development of endothelial dysfunction in
CHF. Indeed, the placebo-controlled data presented here
demonstrate that vitamin C therapy markedly decreases the
plasma load of apoptotic microparticles in patients with CHF
(Figure 3). Because the maintenance of the integrity of the
endothelium can be assumed to be prerequisite for its pre-
served function, we hypothesize that the prevention of en-
hanced EC apoptosis may be 1 mechanism by which vitamin
C protects the vascular wall in CHF.
The profound decrease in circulating apoptotic membrane
microparticles on vitamin C therapy of CHF patients may be
secondary to a reduction in proapoptotic stimuli in the serum
of CHF patients and/or to blockade of intracellular apoptosis
signaling pathway by vitamin C, leading to reduced sensitiv-
ity of ECs to proapoptotic stimuli. In accordance with
previous findings showing inhibition of lipopolysaccharide-
and high glucose–induced EC apoptosis by vitamin C in
vitro,23,24 our observation that vitamin C application inhibits
EC apoptosis when applied ex vivo in cell culture supports an
intracellular mode of action rather than the dependency on a
systemic effect in cell culture. Moreover, because proapoptot-
ic cytokine serum levels did not change on vitamin C
administration, a mechanism that involves the regulation of
cytokine serum levels by vitamin C appears highly unlikely.
In contrast, vitamin C treatment significantly decreases
plasma levels of TBARS as a marker of increased oxidative
stress in CHF patients. In addition, we demonstrate that
vitamin C interferes with intracellular apoptosis signaling at
the level of mitochondrial cytochrome C release and up-
stream of caspase-9 activation. This effect resembles the
intracellular mechanism by which carvedilol, the b-blocking
agent with antioxidative properties, inhibits apoptosis in
activated ECs.9 Mitochondria release cytochrome C in re-
sponse to ROS25 that are either derived from systemic
oxidative stress or produced after TNF-a or Ang II stimula-
tion.12 Thus, antioxidants like vitamin C or carvedilol might
interfere with ROS-mediated cytochrome C liberation by
directly neutralizing, ie, reducing, ROS and/or by increasing
endogenous NO bioavailability.26 NO interferes with proapo-
ptotic signaling via multiple pathways, leading to stabiliza-
tion of the mitochondrial membrane.27,28 Indeed, the present
study demonstrates that the antiapoptotic effect of vitamin C
ex vivo in activated ECs depends to a large degree on the
endogenous bioavailability of NO. We therefore propose that
vitamin C might suppress EC apoptosis by increasing bioac-
tive intracellular NO, which prevents cytochrome C release
and blocks apoptosis signaling.
In conclusion, the inhibition of EC apoptosis by vitamin C
treatment of CHF patients in vivo and of ECs in vitro
provides thorough evidence for a mechanism of clinical
relevance by which vitamin C can interfere with disturbances
in endothelial function. These findings extend the established
involvement of EC death mechanisms in the pathogenesis and
progression of atherosclerotic vascular disease29 to CHF
independent of its cause.
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